Rayaldee (Calcifediol) Patent Expiration, LOE Window & CMS Spending

Rayaldee (Calcifediol) by Eirgen: FDA Orange Book LOE 2034-03-14, 0 AB generics, $48.1M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorEirgen
FDA Application & PathwayN208010 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2034-03-14
Orange Book Patents (*PED Extensions)16 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$48.1M
2024 Medicare Part D Spend$42.8M
2024 Medicaid Spend$5.2M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel